These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8853102)

  • 21. Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients.
    Frink EJ; Malan TP; Morgan SE; Brown EA; Malcomson M; Brown BR
    Anesthesiology; 1992 Dec; 77(6):1064-9. PubMed ID: 1466458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal toxicity with sevoflurane: a storm in a teacup?
    Gentz BA; Malan TP
    Drugs; 2001; 61(15):2155-62. PubMed ID: 11772127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
    Kharasch ED; Schroeder JL; Sheffels P; Liggitt HD
    Anesthesiology; 2005 Dec; 103(6):1183-8. PubMed ID: 16306730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The compound A concentration in a low-flow anesthesia circuit using the new CO2 absorbent SPHERASORB].
    Obata R; Bito H; Katoh T; Sato S
    Masui; 2000 May; 49(5):504-8. PubMed ID: 10846381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partly exhausted soda lime or soda lime with water added, inhibits the increase in compound A concentration in the circle system during low-flow sevoflurane anaesthesia.
    Moriwaki G; Bito H; Ikeda K
    Br J Anaesth; 1997 Dec; 79(6):782-6. PubMed ID: 9496213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The use of lithium hydroxide for carbon dioxide absorption prevents formation of compound A during sevoflurane anesthesia].
    Förster H; Behne M; Warnken UH; Asskali F; Dudziak R
    Anaesthesist; 2000 Feb; 49(2):106-12. PubMed ID: 10756964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro compound A formation in a computer-controlled closed-circuit anesthetic apparatus. Comparison with a classical valve circuit.
    Versichelen LF; Rolly G; Bouche MP; Van Bocxlaer JF; Struys MM; Van Der Herten C; De Leenheer AP; Mortier EP
    Anesthesiology; 2000 Oct; 93(4):1064-8. PubMed ID: 11020762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Kidney function in test subjects: published results and clinical relevance].
    Frink EJ
    Anaesthesist; 1998 Nov; 47 Suppl 1():S33-6. PubMed ID: 9893878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofnolime with different water content causes different effects in two sevoflurane inhalational induction techniques with respect to the output of compound-A.
    Liu SJ; Li Y; Sun B; Wang CS; Gong YL; Zhou YM; Li EY
    Int J Med Sci; 2012; 9(6):435-40. PubMed ID: 22859903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers.
    Ebert TJ; Frink EJ; Kharasch ED
    Anesthesiology; 1998 Mar; 88(3):601-10. PubMed ID: 9523801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral neuropathy in healthy men volunteers anesthetized with 1.25 MAC sevoflurane for 8 hours.
    Goldberg ME; Larijani GE; Eger EI
    Pharmacotherapy; 1999 Oct; 19(10):1173-6. PubMed ID: 10512067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sevoflurane and renal function.
    Malan TP
    Anesth Analg; 1995 Dec; 81(6 Suppl):S39-45. PubMed ID: 7486146
    [No Abstract]   [Full Text] [Related]  

  • 33. Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
    Altuntas TG; Kharasch ED
    Toxicol Appl Pharmacol; 2001 Dec; 177(2):85-93. PubMed ID: 11740907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compound A concentrations during low-flow sevoflurane anesthesia correlate directly with the concentration of monovalent bases in carbon dioxide absorbents.
    Higuchi H; Adachi Y; Arimura S; Kanno M; Satoh T
    Anesth Analg; 2000 Aug; 91(2):434-9. PubMed ID: 10910864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sevoflurane degradation to compound A in anaesthesia breathing systems.
    Cunningham DD; Huang S; Webster J; Mayoral J; Grabenkort RW
    Br J Anaesth; 1996 Oct; 77(4):537-43. PubMed ID: 8942344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism and toxicity of the new anesthetic agents.
    Kharasch ED
    Acta Anaesthesiol Belg; 1996; 47(1):7-14. PubMed ID: 8651050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
    Altuntas TG; Zager RA; Kharasch ED
    Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of sevoflurane with halothane in pediatric ambulatory anesthesia: an experience in Taiwan.
    Chong ZK; Jawan B; Poon YY; Lee JH
    Acta Anaesthesiol Sin; 1997 Mar; 35(1):21-4. PubMed ID: 9212477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A).
    Altuntas TG; Park SB; Kharasch ED
    Chem Res Toxicol; 2004 Mar; 17(3):435-45. PubMed ID: 15025515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sevoflurane low-flow anaesthesia: best strategy to reduce Compound A concentration.
    Di Filippo A; Marini F; Pacenti M; Dugheri S; Focardi L; Novelli GP
    Acta Anaesthesiol Scand; 2002 Sep; 46(8):1017-20. PubMed ID: 12190805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.